Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Medical technology & services

C4X Discovery chief Clive Dix given award for contribution to life sciences

“Clive is a veteran of the UK biotechnology industry with more than 30 years of experience, with a strong track record as a serially successful entrepreneur and an experienced pharmaceutical R&D executive," said C4X Discovery chair Eva-Lott

C4X Discovery Holdings PLC (AIM:C4XD) said its chief executive officer, Dr Clive Dix, has received the Special Recognition Award at the OBN 2021 Awards for his life-long contribution to the UK life sciences industry.

C4X Discovery chair Eva-Lotta Allan said: "The prestigious OBN Awards celebrate the very best of UK life science. We are therefore very proud of all that Clive has achieved throughout his career, and in particular, here at C4XD.

“Clive is a veteran of the UK biotechnology industry with more than 30 years of experience, with a strong track record as a serially successful entrepreneur and an experienced pharmaceutical R&D executive.

“Over the past year, in addition to his corporate work, Clive has played a leading role in the UK Vaccine Taskforce which has been recognised as leading one of the most successful rollouts of the COVID-19 vaccination globally.

“Clive is an inspiration to us here at C4XD and it is wonderful to see the recognition across the industry for all his contributions to our thriving life sciences sector."

READ: C4X Discovery science chief to step down

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK